Clinical Trial

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Study acronym: SEMAHEART
Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2024 (before its estimated July 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patients with heart failure with preserved ejection fraction, and decreased the heart failure hospitalizations in patients with type 2 diabetes. The aim of the present study is to investigate the underlying mechanisms of the beneficial clinical effects of semaglutide in the setting of chronic heart failure.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06541509
Lead Sponsor University Medical Centre Ljubljana
Collaborators: Stanford University, Greenstone Biosciences, Inc.
Conditions Heart Failure, Obesity
Enrollment 10 participants
Start Date 2024-07-10
Primary Completion 2025-07-10 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-07